A Phase II, Multicenter, Open-Label Study Of YM155 Plus Rituximab In Previously Treated Subjects With CD20-Positive B Cell Non-Hodgkin's Lymphoma Who Are Ineligible For Or Have Previously Received An Autologous Stem Cell Transplant

Inclusion Criteria:

- Any stage, histologically confirmed CD20-positive primary or transformed diffuse
large B cell lymphoma (DLBCL)or grade 3 follicular lymphoma (FL)

- Ineligible for or have previously received an autologous stem cell transplant (ASCT)

- Relapsed following receipt of the last dose of systemic chemotherapy or ASCT

- At least one prior chemotherapy regimen. Prior chemotherapy regimen must have
contained anthracycline (unless contraindicated)

- If the subject is female, she must be non-pregnant and non-lactating at the Baseline
Visit. All sexually active males and females of childbearing potential must agree to
use an adequate method of contraception throughout the study period

- Eastern Cooperative Oncology Group (ECOG) performance status
Exclusion Criteria:

- Use of any standard/experimental anti-lymphoma drug therapy within 21 days of the
Baseline Visit

- Use of systemic steroids within 5 days of the Baseline Visit (except for the purposes
of pre-medication prior to study regimen treatment)

- Prior allogeneic stem cell transplant (SCT)

- The subject has been previously treated with YM155

- The subject has known human immunodeficiency virus (HIV), hepatitis B surface
antigen, or hepatitis C antibody

- The subject has received other investigational therapy or procedures within 21 days
prior to the first study drug administration